Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 3826 AL 3840

A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease

Buckley RF, Villemagne VL, Masters CL, Ellis KA, Rowe CC, Johnson K, Sperling R, Amariglio R.

J Mol Neurosci. 2016 Nov;60(3):354-361. doi: 10.1007/s12031-016-0810-z. Epub 2016 Aug 11.

Searching biomarkers for mental disorders-lessons from Alzheimer's disease

Maier W.

Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):583-5. doi: 10.1007/s00406-016-0732-3.

The pertussis hypothesis: Bordetella pertussis colonization in the pathogenesis of Alzheimer's disease

Rubin K, Glazer S.

Immunobiology. 2017 Feb;222(2):228-240. doi: 10.1016/j.imbio.2016.09.017. Epub 2016 Sep 28.

[Clinical Implications and Appropriate Use of Amyloid Imaging with florbetapir ((18)F) in Diagnosis of Patients with Alzheimer Disease]

Nakamura T, Iwata A, Ueda K, Namiki C.

Brain Nerve. 2016 Oct;68(10):1215-1222. doi: 10.11477/mf.1416200578.

Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics

Hickman RA, Faustin A, Wisniewski T.

Neurol Clin. 2016 Nov;34(4):941-953. doi: 10.1016/j.ncl.2016.06.009. Epub 2016 Aug 4.

[Formula: see text]Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status

Machulda MM, Hagen CE, Wiste HJ, Mielke MM, Knopman DS, Roberts RO, Vemuri P, Lowe VJ, Jack CR Jr, Petersen RC.

Clin Neuropsychol. 2017 Jan;31(1):99-117. doi: 10.1080/13854046.2016.1241303. Epub 2016 Oct 11.

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease

Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, Booth K, Shadman A, Brashear HR, Novak G.

J Alzheimers Dis. 2016 Oct 18;54(4):1509-1519. doi: 10.3233/JAD-160369.

Alzheimer disease: Biomarkers of AD risk - the end of the road for plasma amyloid-β?

Wood H.

Nat Rev Neurol. 2016 Nov;12(11):613. doi: 10.1038/nrneurol.2016.160. Epub 2016 Oct 14.

Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes

Mak E, Gabel S, Mirette H, Su L, Williams GB, Waldman A, Wells K, Ritchie K, Ritchie C, O'Brien J.

Ageing Res Rev. 2017 May;35:250-264. doi: 10.1016/j.arr.2016.10.001. Epub 2016 Oct 21.

Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease

Kulic L, Unschuld PG.

Curr Opin Neurol. 2016 Dec;29(6):749-755. doi: 10.1097/WCO.0000000000000399.

Advances in Aβ plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease

Jovalekic A, Bullich S, Catafau A, de Santi S.

Neurodegener Dis Manag. 2016 Dec;6(6):491-497. doi: 10.2217/nmt-2016-0026. Epub 2016 Nov 4.

Peripheral Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease and Mild Cognitive Impairment: a Comprehensive Systematic Review and Meta-analysis

Kim BY, Lee SH, Graham PL, Angelucci F, Lucia A, Pareja-Galeano H, Leyhe T, Turana Y, Lee IR, Yoon JH, Shin JI.

Mol Neurobiol. 2017 Nov;54(9):7297-7311. doi: 10.1007/s12035-016-0192-9. Epub 2016 Nov 4.

Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review

Bemelmans SA, Tromp K, Bunnik EM, Milne RJ, Badger S, Brayne C, Schermer MH, Richard E.

Alzheimers Res Ther. 2016 Nov 10;8(1):46. doi: 10.1186/s13195-016-0212-z.

In Vivo Comparison of Tau Radioligands (18)F-THK-5351 and (18)F-THK-5317

Betthauser TJ, Lao PJ, Murali D, Barnhart TE, Furumoto S, Okamura N, Stone CK, Johnson SC, Christian BT.

J Nucl Med. 2017 Jun;58(6):996-1002. doi: 10.2967/jnumed.116.182980. Epub 2016 Nov 10.

[Alzheimer's disease cerebro-spinal fluid biomarkers: A clinical research tool sometimes useful in daily clinical practice of memory clinics for the diagnosis of complex cases]

Magnin E, Dumurgier J, Bouaziz-Amar E, Bombois S, Wallon D, Gabelle A, Lehmann S, Blanc F, Bousiges O, Hannequin D, Jung B, Miguet-Alfonsi C, Quillard M, Pasquier F, Peoc'h K, Laplanche JL, Hugon J, Paquet C; pour le groupe ePLM (étude des biomarqueurs de la Ponction Lombaire Multicentrique).

Rev Med Interne. 2017 Apr;38(4):250-255. doi: 10.1016/j.revmed.2016.10.383. Epub 2016 Nov 24.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias